Overall, these results suggest that, unlike other tumor types, MSI CRCs with B2M and JAK1/2 mutations are responsive to PD-1 inhibitors, indicating that the mechanism of resistance to anti-PD-1 therapy in CRC may be different from that in other solid tumors [68]. This evidence concerns the gene JAK1 and colorectal carcinoma.